High value niche Kona Medical offers a non-invasive renal denervation solution for hypertension, presenting a compelling savings and safety proposition for hospitals and clinics seeking to reduce procedural complexity, radiation exposure, and cath lab reliance.

Private capital traction With existing funding around ten million dollars and backing from medical technology investors, Kona has demonstrated financial backing to advance regulatory progression, clinical trials, and market development efforts that align with sales cycles in large health systems.

Private market readiness The company targets medical facilities that value cutting-edge ultrasound-guided therapies; sales efforts can focus on decision makers in hypertension programs, interventional radiology, and cardiology departments seeking innovative, cost-reducing hypertension treatments.

Clinical momentum Clinical trial promise and an excellent safety profile position Kona to engage health systems during study expansions, payer discussions, and implementation planning for hypertension management pathways that integrate non-invasive alternatives.

Expansion potential As a smaller, growth-oriented player in a field dominated by large device manufacturers, Kona can pursue strategic partnerships, distribution agreements, and co-development opportunities with bigger players to accelerate adoption in target markets.